Applied nanotechnology for the management of breakthrough cancer pain

Minerva Anestesiologica

Volumn 71, Issue 7-8, 2005, Pages 419-423

  Sprintz, M ^a   Benedetti, C ^a   Ferrari, M ^b,c  

^a OHIO STATE UNIVERSITY   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c OHIO STATE UNIVERSITY   (United States)

Author keywords

Drug delivery; Nanotechnology; Neoplasms; Pain, prevention and control

Indexed keywords

FENTANYL CITRATE; MORPHINE; NARCOTIC ANALGESIC AGENT; REMIFENTANIL;

ARTICLE; BIOMEDICAL ENGINEERING; BIOMEDICAL TECHNOLOGY ASSESSMENT; CANCER PAIN; CANCER PREVENTION; CANCER SCREENING; CONTROLLED RELEASE FORMULATION; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG HALF LIFE; DRUG METABOLISM; EARLY DIAGNOSIS; HUMAN; LONG TERM CARE; NANOTECHNOLOGY; PATHOPHYSIOLOGY; RESPIRATION DEPRESSION; WELLBEING;

ANIMALS; DRUG DELIVERY SYSTEMS; HUMANS; NANOTECHNOLOGY; NEOPLASMS; PAIN;

EID: 33745314793     PISSN: 03759393     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Benedetti C. Pain: the magnitude of the problem and unmet therapeutic needs. Biomed Microdevices 2001; 3:125-32.
2. National Cancer Institute. US Estimated Complete Prevalence Counts on 1/ 1/2001. http://seer.cancer.gov/faststats/html/pre_all.html
3. Bonica J. The management of pain. Philadelphia: Lea & Febiger;1990.
4. Fine PG. Breakthrough cancer pain. CNS Drugs 2000;13:313-9.
5. Caraceni A, Martini C, Zecca E, Portenoy RK, Ashby MA, Hawson G et al. Breakthrough pain characteristics and syndromes in patients with cancer pain. An international survey. Palliat Med 2004; 18:177-83.
6. Portenoy RK, Hagen NA. Breakthrough pain: definition, prevalence and characteristics. Pain 1990;41:273-81.
7. Portenoy RK, Payne D, Jacobsen P. Breakthrough pain: characteristics and impact in patients with cancer pain. Pain 1999;81:129-34.
8. Zeppetella G, O'Doherty CA, Collins S. Prevalence and characteristics of breakthrough pain in cancer patients admitted to a hospice. J Pain Symptom Manage 2000; 20:87-92.
9. Hwang SS, Chang VT, Kasimis B. Cancer breakthrough pain characteristics and responses to treatment at a VA medical center. Pain 2003;101:55-64.
10. Payne R, Coluzzi P, Hart L, Simmonds M, Lyss A, Rauck R et al. Long-term safety of oral transmucosal fentanyl citrate for breakthrough cancer pain. J Pain Symptom Manage 2001;22:575-83.
11. Colluzzi PH, Schwartzberg L, Conroy Jr JD, Charapata S, Gay M, Busch MA et al. Breakthrough cancer pain: a randomized trial comparing oral transmucosal fentanyl citrate (OTFC) and morphine sulfate immediate release (MSIR). Pain 2001;91:23-30.
12. Cingolani R, Rinaldi R, Maruccio G, Biasco A. Nanotechnology approaches to self-organized biomolecular devices. Physica E 2002;13:1229-35.
13. Watanabe K, Takemura Y, Shimazu Y, Shirakashi J. Magnetic nanostructures fabricated by the atomic force microscopy nano-lithography technique. Nanotechnology 2004; 15:S566-9.
14. Colbert DT, Smalley R. Fullerene nanotubes for molecular electronics. Trends Biotechnol 1999;17:46-50.
15. Dresselhaus MS, Dresselhaus G. Nanotechnology in carbon materials. Nanostructured Materials 1997;9:33-42.
16. Cohen MH, Melnik K, Boiarski AA, Ferrari M, Martin FJ. Microfabrication of silicon-based nanoporous particulates for medical applications. Biomed Microdevices 2003; 5:253-9.
17. Wei YY, Eres G. Directed assembly of carbon nanotube electronic circuits. Appl Phys Lett 2000;76:3759-61.
18. Stoltenberg RM, Wolley AT. DNA-templated nanowire fabrication. Biomed Microdevices 2004;6:105-11.
19. Pang YT, Shan WJ, Zhang LD, Gao XY, Zhao AW et al. Arrays of ordered Ag nanowires with different diameters in different areas embedded in one piece of anodic alumina membrane. Appl Phys Lett A Materials Science Processing 2003;77:717-20.
20. Roco M. International strategy for nanotechnology research and development. J Nanoparticle Res 2001;3:353-60.
21. Baker JR, Quintana A, Piehler L, Banaszak-Holl M, Tomalia D, Raczka E et al. The Synthesis and testing of anti-cancer therapeutic nanodevices. Biomed Microdevices 2001;3:61-9.
22. Zhao Z, Wang J, Mao HQ, Leong KW. Polyphosphoesters in drug and gene delivery. Adv Drug Deliv Rev 2003;55:483-99.
23. Bogglid P, Tanasa C, Grey F. Fabrication and actuation of customized nanotweezers with a 25nm gap. Nanotechnology 2001;12:331-35.
24. Soundarrajan P, Dai L. Surface modification of aligned carbon nanotube arrays for electrochemical sensing applications. J Vac Sci Technol 2003;21:1198-201.
25. Li K, Guccione S, Bednarski M. Combined vascular targeted imaging and therapy: a paradigm for personalized treatment. J Cell Biochem Suppl 2002;39:65-71.
26. Zhang Y, Kohler N, Zhang M. Surface modification of superparamagnetic magnetite nanoparticles and their intracellular uptake. Biomaterials 2002;23:1553-61.
27. Wickline SA, Lanza GM. Molecular imaging, targeted therapeutics, and nanoscience. J Cell Biochem Suppl 2002;39:90-7.
28. National Cancer Institute. http://nano.cancer.gov/alliance_cancer-nanotechnology-plan.asp
29. Burton AW, Cleeland CS. Cancer pain: progress since WHO guidelines. Pain Practice 2001;1:236-42.
30. Lee M, Kern SE, Kisicki JC, Egan TD. A pharmacokinetic study to compare two simultaneous 400 μg doses with a single 800 μg dose of oral transmucosal fentanyl citrate. J Pain Symptom Manage 2003;26:743-7.
31. Zhang H, Zhang J, Streisand JB. Oral mucosal drug delivery: clinical pharmacokinetics and therapeutic applications. Clin Pharmacokinet 2002;41:661-80.
32. Grond S, Radbruch L, Lehmann KA. Clinical pharmacokinetics of transdermal opioids. Focus on transdermal fentanyl. Clin Pharmacokinet 2000;38:59-89.
33. Tao SL, Desai TA. Microfabricated drug delivery systems: from particles to pores. Adv Drug Deliv Rev 2003;55:315-28.
34. Desai TA, Hansford D, Ferrari M. Characterization of micromachined silicon membranes for immunoisolation and bioseparation applications. Jf Membrane Sci 1999; 159:221-31.
35. Michelsen LG, Hug Jr CC. The pharmacokinetics of remifentanil. J Clin Anesth 1996; 8:679-82.
36. Glass PSA. Remifentanil: a new opioid. J Clin Anesth 1995;7:558-63.
37. Gravel NR, Searle NR, Sahab PG, Carrier M. Sedation in critically ill patients: practical recommendations. CNS Drugs 1999;11:9-22.
38. Tegeder I, Lötsch J, Geisslinger G. Pharmacokinetics of opioids in liver disease. Clin Pharmacokinet 1999;37:17-40
39. Hoogstraate JAJ, Wertz PW. Drug delivery via the buccal mucosa. Pharm Sci Technol Today 1998;1:309-16.